FDA Approves Glenmark’s Generic Potassium Chloride Tablets

FDA approval#1

Glenmark Pharmaceuticals has announced receiving approval from the FDA to produce Potassium Chloride Extended Release Tablets. The tablets are used to treat patients suffering from low levels of potassium in the blood. The drug is a generic version of Merck’s K-Dur extended release tablets. According to IMS Health data, K-Dur had annual sales of $283.2 million for the 12 months prior to May of 2016.

Read the source article at The Financial Express

About the Author

Related Posts

Leave a Reply